A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
The main purpose of this study is to find out if DCVAC/PCa when given with standard of care chemotherapy makes people with prostate cancer live longer than giving the standard of care chemotherapy and a placebo. DCVAC/PCa is an immunotherapy - this means that it is similar to a vaccine in that it is designed to train your white blood cells to fight against your disease.
Metastatic Castration-Resistant Prostate Cancer (CRPC) that is eligible to receive docetaxel chemotherapy.
Prostate Cancer that has spread outside the prostate and is no longer responding to hormonal therapies.
Eligible to receive Standard of Care chemotherapy.
Patients who are HIV or HTLV positive, or have active heptatitis B, hepatitis C, or syphilis are excluded.
18 - 99
Healthy Volunteers Needed
Duration of Participation
OHSU Knight Clinical Trials Information Line